MD

Business Context and Reporting Period

Pediatrix Medical Group, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2002. The company operates as a national provider of pediatric medical services, managing physician group practices. As of November 11, 2002, there were 25,237,903 shares of common stock outstanding.

Key Financial Metrics

The following table summarizes the financial performance for the three and nine months ended September 30, 2002, compared to the prior year periods (in thousands, except per share data):

Liquidity: The company maintained a $100 million line of credit with no outstanding balance as of September 30, 2002. Net cash provided by operating activities for the nine months ended September 30, 2002, was $67.2 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 19.2% for the quarter and 38.5% for the nine-month period. Growth was driven by acquisitions (including six new physician groups in 2002) and a 14.7% to 16.9% increase in same-unit revenue due to price increases, improved collection rates, and higher patient days.
• Profitability Surge: Net income more than doubled for the quarter (up 87.4%) and increased 145% for the nine-month period. A primary driver was the adoption of FAS 142, which eliminated goodwill amortization expense. Depreciation and amortization dropped 76% for the quarter and 70.4% for the nine months compared to 2001.
• Expense Management: Operating margins expanded significantly (6.3 percentage points for the quarter). General and administrative expenses as a percentage of revenue declined, offsetting increases in practice salaries and benefits driven by volume growth and new acquisitions.
• Capital Allocation: The company completed a $50 million common stock repurchase program in July 2002, acquiring approximately 1.7 million shares.

Guidance, Outlook, Risks, and Contingencies

Outlook: Management anticipates that funds from operations, cash on hand, and the available line of credit will be sufficient to meet working capital and capital expenditure requirements for the next 12 months. No specific numerical guidance for future periods was provided in this filing.

Risks and Contingencies:

• Regulatory Investigations: The company is cooperating with a Federal Trade Commission (FTC) investigation regarding competition issues following the MAGELLA Healthcare merger. Additionally, a TRICARE investigation into billing practices is active. The company cannot predict the outcome or material impact of these investigations.
• Settlements: The company settled a securities class action litigation for $12.0 million (paid in 2002) and a Colorado Medicaid investigation for $1.3 million.
• Insurance Costs: The company expects significant increases in professional liability and directors and officers insurance premiums upon renewal in 2003.
• Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ due to factors such as reimbursement rate changes, physician retention, and integration of acquisitions.

Investor Verification Checklist

• Verify the impact of the FTC investigation on future merger activity and potential antitrust penalties.
• Confirm the status of the TRICARE billing investigation and potential exposure in other state Medicaid programs.
• Assess the sustainability of same-unit revenue growth (14.7% - 16.9%) given the one-time nature of price increases implemented in 2001.
• Review the stock repurchase program completion and its effect on future share count and EPS dilution.
• Monitor upcoming insurance premium renewals (April 2003 for liability, November 2002 for D&O) for potential margin compression.